



Reg. Office: 28, Level 1, am @ 10, MB Towers, H No. 8-2-624/A/1, Road No. 10, Banjara Hills, Hyderabad – 500034, Telangana
Corp Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai – 400053
Email ID: rubraltd@gmail.com | **Website:** www.rubramed.com
CIN: L33100TG1991PLC013266 | **Tel:** +91 9167469649

May 28, 2018

To,

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : **531099**
Sub : **Outcome of Board Meeting**

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Monday, May 28, 2018 inter alia, has considered and approved the following:

1. Audited Standalone Financial Results for the year ended March 31, 2018 along with the Audit Report thereon;
2. Appointment of Mr. Sunil Khandelwal as Managing Director of the Company;
3. Appointment of Mr. Manish Gandhi as Independent Non-executive Director;
4. Acceptance of resignation of Mr. Ashok Sahu as Independent Non-executive Director;
5. Appointment of Ms. Priti Surti as the Company Secretary and Compliance Officer of the Company.

Further, pursuant to sub-regulation 2 of Regulation 30 read with clause 7 of Para A of Part A of the schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Disclosures for Change in Directors and Key Managerial Personnel's, are as under:

1. Mr. Sunil Khandelwal is appointed as Managing Director for a period of 3 years. He has over 35 years of progressive experience in Hospitality Industry, Strategic planning, improving operation efficiency and running business successfully. He is not related to any other Director of the Company and is also not a Director in any other listed Company. He or his relatives do not hold any shares in the Company.
2. Mr. Manish Gandhi is appointed as Independent Non-Executive Director. He has 12 years of extensive experience in cross border trading of goods and logistics. He is not related to any other Director of the Company and is also not a Director in any other listed Company. He or his relatives do not hold any shares in the Company.
3. Mr. Ashok Sahu resigned as Director of the Company on May 28, 2018 due to pre-occupancy.
4. Ms. Priti Surti is appointed as Company Secretary and Compliance Officer. She has experience of more than 1 year in Legal, Compliance and Secretarial field. She or her relatives do not hold any shares in the Company.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



Abha Kapoor
Director (Finance) and Chief Financial Officer
DIN – 02799429

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2018

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for current period ended	Figures for previous period ended
		31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	34.08	0.00	5.74	229.80	30.62
II	Other Income	0.00	0.00	0.25	15.98	0.25
III	Total Income (I + II)	34.08	0.00	5.99	245.78	30.87
IV	Expenses:					
	Cost of Materials Consumed	0.17	0.00	0.00	101.70	0.00
	Purchases of Stock in Trade	0.00	0.00	0.00	86.94	12.13
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	4.50	5.06	0.70	12.96	2.00
	Finance Costs	0.00	0.00	0.01	0.00	0.01
	Depreciation & amortisation expense	0.01	0.01	0.01	0.04	0.03
	Other Expenses	15.92	4.06	4.42	31.69	13.31
	Total Expenses (IV)	20.60	9.13	5.14	233.33	27.48
V	Profit / (loss) before exceptional items and tax (III-IV)	13.48	-9.13	0.85	12.45	3.39
VI	Exceptional Items	-28.82	0.00	0.00	-28.82	0.00
VII	Profit / (loss) before tax (V-VI)	-15.34	-9.13	0.85	-16.37	3.39
VIII	Tax Expense:					
	(1) Current tax	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00
	Profit (Loss) for the period from continuing operations (VII-VIII)	-15.34	-9.13	0.85	-16.37	3.39
IX	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	-15.34	-9.13	0.85	-16.37	3.39
XIV	Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-15.34	-9.13	0.85	-16.37	3.39
XVI	Earnings per equity share (for continuing operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.02 0.02	0.00 0.00	0.06 0.06
XVII	Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
XVIII	Earnings per equity share (for discontinued & continuing operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.02 0.02	0.00 0.00	0.06 0.06
NOTES:						
1 The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
2 The Segment - wise details are not applicable to the Company as the Company has no segments.						
3 The results are Ind-AS compliant however, the previous year figures are not subject to limited review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.						
4 Loss during the quarter is due to write off of receivables and payables						
5 Previous period's figures have been reclassified / regrouped, wherever necessary.						

For Rubra Medicaments Limited




Abha Kapoor
 Director (Finance) & CFO
 DIN: 02799429

Place: Mumbai
Date:- May 28, 2018

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

	Particulars	Figures as at the end of current reporting period	Figures as at the end of the previous reporting period
		March 31, 2018	March 31, 2017
		Audited	Audited
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	0.05	0.08
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	-	33.79
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	1.77	1.69
	Total non-current assets	1.82	35.56
2	Current assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	34.37	1.77
	(iii) Cash and cash equivalents	29.74	15.55
	(iv) Bank balances other than (iii) above	3.89	-
	(v) Loans	11.50	-
	(vi) Others to be specified	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	-	-
	Total current assets	79.50	17.32
	Total assets	81.32	52.88
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-487.64	-505.03
	Total equity	59.19	41.80
	LIABILITIES		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	0.01	7.47
	(d) Other non-current liabilities	-	-
	Total non-current liabilities	0.01	7.47
	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	16.57	3.32
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Other current liabilities	-	-
	(c) Provisions, current	5.55	0.29
	(d) Current tax liabilities (Net)	-	-
	Total current liabilities	22.12	3.61
	Total liabilities	22.13	11.08
	Total Equity and Liabilities	81.32	52.88



Handwritten signature/initials in blue ink.

**Auditor's Report On Financial Results of the Company Pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

To
The Board of Directors
Rubra Medicaments Ltd.

We have audited the financial results of Rubra Medicaments Ltd. for the year ended March 31, 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the year ended March 31, 2018

For Prakash Modi & Associates
Chartered Accountants
FRN: 116900W

Prakash Modi

Prakash Modi
Partner
M. No. 101463



Date: May 28, 2018

May 28, 2018

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code : 531099
Sub : Declaration on the Independent Auditors' Report with unmodified opinion pursuant to Regulation 33 (3)(d) of the SEBI (LODR) Regulations, 2015

DECLARATION

I, Abha Kapoor, Director (Finance) & CFO of the Company hereby declare that, the Statutory Auditors of the Company have issued an Independent Audit Report with unmodified/unqualified opinion on Annual Audited Standalone Financial Results of the Company for the year ended March 31, 2018.

For **Rubra Medicaments Limited**



Abha Kapoor
Director (Finance) & CFO
DIN - 02799429